Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging.

Pandey MK, DeGrado TR.

Theranostics. 2016 Feb 17;6(4):571-93. doi: 10.7150/thno.14334. eCollection 2016. Review.

2.

HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase.

Kadri F, Pacifici M, Wilk A, Parker-Struckhoff A, Del Valle L, Hauser KF, Knapp PE, Parsons C, Jeansonne D, Lassak A, Peruzzi F.

J Biol Chem. 2015 Dec 25;290(52):30931-46. doi: 10.1074/jbc.M115.675751. Epub 2015 Nov 3.

3.

Mass spectrometric phosphoproteome analysis of HIV-infected brain reveals novel phosphorylation sites and differential phosphorylation patterns.

Uzasci L, Auh S, Cotter RJ, Nath A.

Proteomics Clin Appl. 2016 Feb;10(2):126-35. doi: 10.1002/prca.201400134. Epub 2015 Aug 12.

4.

Mechanisms of HIV-1 Tat neurotoxicity via CDK5 translocation and hyper-activation: role in HIV-associated neurocognitive disorders.

Fields JA, Dumaop W, Crews L, Adame A, Spencer B, Metcalf J, He J, Rockenstein E, Masliah E.

Curr HIV Res. 2015;13(1):43-54. Review.

5.

GSK3β-activation is a point of convergence for HIV-1 and opiate-mediated interactive neurotoxicity.

Masvekar RR, El-Hage N, Hauser KF, Knapp PE.

Mol Cell Neurosci. 2015 Mar;65:11-20. doi: 10.1016/j.mcn.2015.01.001. Epub 2015 Jan 20.

6.

Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Beurel E, Grieco SF, Jope RS.

Pharmacol Ther. 2015 Apr;148:114-31. doi: 10.1016/j.pharmthera.2014.11.016. Epub 2014 Nov 27. Review.

7.

The role of tau protein in HIV-associated neurocognitive disorders.

Brown LA, Scarola J, Smith AJ, Sanberg PR, Tan J, Giunta B.

Mol Neurodegener. 2014 Oct 10;9:40. doi: 10.1186/1750-1326-9-40. Review.

8.

Adjunctive and long-acting nanoformulated antiretroviral therapies for HIV-associated neurocognitive disorders.

Gendelman HE, Gelbard HA.

Curr Opin HIV AIDS. 2014 Nov;9(6):585-90. doi: 10.1097/COH.0000000000000111. Review.

9.

Neuroprotective effects of the anti-cancer drug sunitinib in models of HIV neurotoxicity suggests potential for the treatment of neurodegenerative disorders.

Wrasidlo W, Crews LA, Tsigelny IF, Stocking E, Kouznetsova VL, Price D, Paulino A, Gonzales T, Overk CR, Patrick C, Rockenstein E, Masliah E.

Br J Pharmacol. 2014 Dec;171(24):5757-73. doi: 10.1111/bph.12875.

10.

Targeting platelet-derived soluble CD40 ligand: a new treatment strategy for HIV-associated neuroinflammation?

Davidson DC, Jackson JW, Maggirwar SB.

J Neuroinflammation. 2013 Dec 1;10:144. doi: 10.1186/1742-2094-10-144. Review.

11.

Improving lithium therapeutics by crystal engineering of novel ionic cocrystals.

Smith AJ, Kim SH, Duggirala NK, Jin J, Wojtas L, Ehrhart J, Giunta B, Tan J, Zaworotko MJ, Shytle RD.

Mol Pharm. 2013 Dec 2;10(12):4728-38. doi: 10.1021/mp400571a. Epub 2013 Nov 18.

12.

Discovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.

Goodfellow VS, Loweth CJ, Ravula SB, Wiemann T, Nguyen T, Xu Y, Todd DE, Sheppard D, Pollack S, Polesskaya O, Marker DF, Dewhurst S, Gelbard HA.

J Med Chem. 2013 Oct 24;56(20):8032-48. doi: 10.1021/jm401094t. Epub 2013 Oct 3.

13.

Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.

King MK, Pardo M, Cheng Y, Downey K, Jope RS, Beurel E.

Pharmacol Ther. 2014 Jan;141(1):1-12. doi: 10.1016/j.pharmthera.2013.07.010. Epub 2013 Jul 31. Review.

14.

Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells.

Lee SH, Yoon J, Shin SH, Zahoor M, Kim HJ, Park PJ, Park WS, Min do S, Kim HY, Choi KY.

PLoS One. 2012;7(4):e34152. doi: 10.1371/journal.pone.0034152. Epub 2012 Apr 10.

15.

Autophagy in dementias.

Kragh CL, Ubhi K, Wyss-Coray T, Masliah E.

Brain Pathol. 2012 Jan;22(1):99-109. doi: 10.1111/j.1750-3639.2011.00545.x. Review. Erratum in: Brain Pathol. 2012 Mar;22(2):259. Wyss-Corey, Tony [corrected to Wyss-Coray, Tony].

16.

Deconstructing GSK-3: The Fine Regulation of Its Activity.

Medina M, Wandosell F.

Int J Alzheimers Dis. 2011;2011:479249. doi: 10.4061/2011/479249. Epub 2011 Apr 28.

17.

IFN-gamma mediates enhancement of HIV replication in astrocytes by inducing an antagonist of the beta-catenin pathway (DKK1) in a STAT 3-dependent manner.

Li W, Henderson LJ, Major EO, Al-Harthi L.

J Immunol. 2011 Jun 15;186(12):6771-8. doi: 10.4049/jimmunol.1100099. Epub 2011 May 11.

18.

Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine.

Patrick C, Crews L, Desplats P, Dumaop W, Rockenstein E, Achim CL, Everall IP, Masliah E.

Am J Pathol. 2011 Apr;178(4):1646-61. doi: 10.1016/j.ajpath.2010.12.033.

19.

Editorial neuroAIDS review.

Shapshak P, Kangueane P, Fujimura RK, Commins D, Chiappelli F, Singer E, Levine AJ, Minagar A, Novembre FJ, Somboonwit C, Nath A, Sinnott JT.

AIDS. 2011 Jan 14;25(2):123-41. doi: 10.1097/QAD.0b013e328340fd42. Review. No abstract available.

20.

Human immunodeficiency virus-1 Tat activates calpain proteases via the ryanodine receptor to enhance surface dopamine transporter levels and increase transporter-specific uptake and Vmax.

Perry SW, Barbieri J, Tong N, Polesskaya O, Pudasaini S, Stout A, Lu R, Kiebala M, Maggirwar SB, Gelbard HA.

J Neurosci. 2010 Oct 20;30(42):14153-64. doi: 10.1523/JNEUROSCI.1042-10.2010.

Supplemental Content

Support Center